Myopic Choroidal Neovascularization

Ophthalmology 124, 1690-1711 DOI: 10.1016/j.ophtha.2017.04.028

Citation Report

#	Article	IF	CITATIONS
1	Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. British Journal of Ophthalmology, 2004, 88, 1315-1319.	2.1	70
2	Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 13-19.	1.0	59
3	Choroidal neovascularisation in pathological myopia: an update in management. British Journal of Ophthalmology, 2005, 89, 1522-1528.	2.1	86
4	Choroidal Neovascularization in Pathologic Myopia: Three-Year Results After Photodynamic Therapy. American Journal of Ophthalmology, 2005, 140, 416.e1-416.e.	1.7	47
5	Scleral Buckling With Macular Plombe for Eyes With Myopic Macular Retinoschisis and Retinal Detachment Without Macular Hole. American Journal of Ophthalmology, 2006, 142, 483-487.	1.7	65
6	Indocyanine Green Angiographic Features of Myopic Subfoveal Choroidal Neovascularization as a Prognostic Factor after Photodynamic Therapy. Korean Journal of Ophthalmology: KJO, 2006, 20, 18.	0.5	6
7	PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2006, 26, 746-751.	1.0	48
8	Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West. Japanese Journal of Ophthalmology, 2006, 50, 161-169.	0.9	39
9	Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1474-1479.	1.0	33
10	Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. British Journal of Ophthalmology, 2007, 91, 157-160.	2.1	137
11	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. British Journal of Ophthalmology, 2007, 91, 174-179.	2.1	48
12	Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. British Journal of Ophthalmology, 2007, 91, 161-165.	2.1	135
13	PHOTODYNAMIC THERAPY FOR TAIWANESE PATIENTS WITH PATHOLOGIC MYOPIA:. Retina, 2007, 27, 839-845.	1.0	24
14	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. British Journal of Ophthalmology, 2007, 91, 128-130.	2.1	17
15	Intravitreal Bevacizumab (Avastin) as Primary Treatment for Myopic Choroidal Neovascularization. European Journal of Ophthalmology, 2007, 17, 620-626.	0.7	42
16	Development of Macular Hole and Macular Retinoschisis in Eyes with Myopic Choroidal Neovascularization. American Journal of Ophthalmology, 2008, 145, 155-161.e1.	1.7	36
17	Photodynamic Therapy with Verteporfin for Choroidal Neovascularization of Pathologic Myopia in Japanese Patients: Comparison with Nontreated Controls. American Journal of Ophthalmology, 2008, 145, 518-526.e1.	1.7	41
18	Management of choroidal neovascularization in myopic macular degeneration. Expert Review of Ophthalmology, 2008, 3, 311-323.	0.3	2

#	Article	IF	CITATIONS
19	LACQUER CRACK FORMATION AND CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA. Retina, 2008, 28, 1124-1131.	1.0	97
20	Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 609-618.	1.0	26
22	Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye, 2009, 23, 334-338.	1.1	44
23	Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology, 2009, 54, 372-400.	1.7	125
24	Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year Results. American Journal of Ophthalmology, 2009, 147, 94-100.e1.	1.7	160
25	Central Retinal Sensitivity After Intravitreal Injection of Bevacizumab for Myopic Choroidal Neovascularization. American Journal of Ophthalmology, 2009, 147, 816-824.e1.	1.7	40
26	Comparison of Visual Outcome and Regression Pattern of Myopic Choroidal Neovascularization After Intravitreal Bevacizumab or After Photodynamic Therapy. American Journal of Ophthalmology, 2009, 148, 396-408.e1.	1.7	74
27	Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmologica, 2009, 87, 460-463.	0.6	17
28	ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA. Retina, 2009, 29, 1062-1066.	1.0	100
29	INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING PATHOLOGIC MYOPIA. Retina, 2010, 30, 399-406.	1.0	68
30	MICROPERIMETRIC RETINAL CHANGES IN MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH INTRAVITREAL RANIBIZUMAB. Retina, 2010, 30, 413-417.	1.0	23
31	Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 497-502.	1.0	5
32	Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 543-550.	1.0	38
33	Long-term Pattern of Progression of Myopic Maculopathy. Ophthalmology, 2010, 117, 1595-1611.e4.	2.5	408
34	Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial. American Journal of Ophthalmology, 2010, 149, 458-464.e1.	1.7	102
35	Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization. Acta Ophthalmologica, 2011, 89, 459-462.	0.6	21
36	DIFFERENT DOSING OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION BECAUSE OF PATHOLOGIC MYOPIA. Retina, 2011, 31, 880-886.	1.0	35
37	Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye, 2011, 25, 375-381.	1.1	56

	CITATION RE	PORT	
#	ARTICLE	IF	CITATIONS
38	North-African population. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 1287-1293.	1.0	14
39	Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye, 2012, 26, 976-982.	1.1	51
40	IL-27 inhibits pathophysiological intraocular neovascularization due to laser burn. Journal of Leukocyte Biology, 2011, 91, 267-273.	1.5	18
41	The Prevalence and Impact of High Myopia. Eye and Contact Lens, 2012, 38, 188-196.	0.8	63
42	PROGNOSTIC FACTORS FOR VISUAL OUTCOME AFTER INTRAVITREAL ANTI-VEGF INJECTION FOR NAIVE MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2012, 32, 949-955.	1.0	28
43	TWO-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN JAPANESE PATIENTS WITH PATHOLOGIC MYOPIA. Retina, 2012, 32, 687-695.	1.0	51
44	Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 1717-1723.	1.0	26
45	Intrachoroidal Cavitation in Macular Area of Eyes With Pathologic Myopia. American Journal of Ophthalmology, 2012, 154, 382-393.	1.7	83
46	Choroidal neovascularization in pathological myopia. Progress in Retinal and Eye Research, 2012, 31, 495-525.	7.3	218
47	Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Canadian Journal of Ophthalmology, 2012, 47, 28-33.	0.4	33
48	Comparison between Anti-Vascular Endothelial Growth Factor Therapy and Photodynamic Therapy for Myopic Choroidal Neovascularization. European Journal of Ophthalmology, 2012, 22, 210-215.	0.7	7
49	Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 989-997.	1.0	15
50	Recent trends in the management of maculopathy secondary to pathological myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 3-13.	1.0	26
51	Choroidal Thickness after Treatment for Myopic Choroidal Neovascularization. European Journal of Ophthalmology, 2013, 23, 887-898.	0.7	14
52	Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1-7.	1.0	55
53	Prognostic Factors of Eyes With NaÃ ⁻ ve Subfoveal Myopic Choroidal Neovascularization After Intravitreal Bevacizumab. American Journal of Ophthalmology, 2013, 156, 1201-1210.e2.	1.7	58
54	Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye, 2013, 27, 709-715.	1,1	45
55	INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2013, 33, 1375-1392.	1.0	67

ARTICLE IF CITATIONS # INTRAVITREAL PEGAPTANIB SODIUM (MACUGEN) FOR TREATMENT OF MYOPIC CHOROIDAL 1.0 21 56 NEOVASCULARIZATION. Retina, 2013, 33, 397-402. INTRAVITREAL BEVACIZUMAB FOR EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO 1.0 PATHOLOGIC MYOPIA. Retina, 2013, 33, 593-597. Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and 58 0.6 26 without Choroidal Neovascularization. Journal of Ophthalmology, 2013, 2013, 1-5. Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal 59 neovascularization. Eye, 2014, 28, 17-22. Photodynamic Therapy in Subfoveal and Juxtafoveal Myopic Choroidal Neovascularization: A 10-year 60 1.0 15 Retrospective Analysis. Ophthalmologica, 2014, 231, 204-210. Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization. Ophthalmologica, 2014, 231, 211-220. 1.0 Blockage of tissue factor ameliorates the lesion of laser-induced choroidal neovascularization in 62 1.2 11 mice. Experimental Eye Research, 2014, 127, 117-123. Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal 0.6 neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmology, 2014, 14, 69. Vascular Endothelial Growth Factor Gene and the Response to Anti-Vascular Endothelial Growth 2.5 27 64 Factor Treatment for Choroidal Neovascularization in High Myopia. Ophthalmology, 2014, 121, 225-233. Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia. Experimental and Therapeutic Medicine, 2015, 10, 0.8 1121-1126. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL 67 1.0 55 NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2015, 35, 2450-2456. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL 1.0 68 28 BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2015, 35, 2457-2468. Current and emerging treatment options for myopic choroidal neovascularization. Clinical 69 0.9 21 Ophthalmology, 2015, 9, 733. International Photographic Classification and Grading System for Myopic Maculopathy. American Journal of Ophthalmology, 2015, 159, 877-883.e7. 1.7 549 Comparison of Clinical Features in Highly Myopic Eyes with and without a Dome-Shaped Macula. 71 2.593 Ophthalmology, 2015, 122, 1591-1600. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization. 189 Ophthalmology, 2015, 122, 1220-1227. Myopic choroidal neovascularisation: current concepts and update on clinical management. British 73 2.1 135 Journal of Ophthalmology, 2015, 99, 289-296. Choroidal thickness and high myopia: a cross-sectional study and meta-analysis. BMC Ophthalmology, 74 2015, 15, 70.

			6
#		IF	CITATIONS
75	Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia. Eye and Contact Lens, 2016, 42, 48-55.	0.8	37
76	Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. Drugs, 2016, 76, 1119-1133.	4.9	8
77	The Prevalence of Myopic Choroidal Neovascularization in the United States. Ophthalmology, 2016, 123, 1771-1782.	2.5	43
78	Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. The Cochrane Library, 2016, 2016, CD011160.	1.5	25
79	MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2016, 36, 1614-1621.	1.0	37
80	Epidemiology of Myopia. Asia-Pacific Journal of Ophthalmology, 2016, 5, 386-393.	1.3	216
81	SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2016, 36, 2140-2149.	1.0	16
82	Macular Bruch Membrane Holes in Choroidal Neovascularization–Related Myopic Macular Atrophy by Swept-Source Optical Coherence Tomography. American Journal of Ophthalmology, 2016, 162, 133-139.e1.	1.7	67
83	Clinical characteristics and visual outcome of macular hemorrhage in pathological myopia with or without choroidal neovascularization. Taiwan Journal of Ophthalmology, 2016, 6, 136-140.	0.3	3
84	The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook. Expert Opinion on Biological Therapy, 2016, 16, 477-487.	1.4	13
85	Updates of pathologic myopia. Progress in Retinal and Eye Research, 2016, 52, 156-187.	7.3	380
86	Macular Bruch Membrane Holes in Highly Myopic Patchy Chorioretinal Atrophy. American Journal of Ophthalmology, 2016, 166, 22-28.	1.7	75
87	Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study. Japanese Journal of Ophthalmology, 2017, 61, 159-168.	0.9	7
88	FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2017, 37, 1931-1941.	1.0	18
89	FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2017, 37, 2056-2061.	1.0	13
90	Success of Intravitreal Ranibizumab for Myopic Choroidal Neovascularization After 2 Years of Treatment. Journal of Vitreoretinal Diseases, 2017, 1, 122-125.	0.2	1
91	Myopic Choroidal Neovascularization. Ophthalmology, 2017, 124, 1690-1711.	2.5	263
92	Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 529-539.	1.0	11

#	Article	IF	CITATIONS
93	Anti–Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization. Asia-Pacific Journal of Ophthalmology, 2017, 6, 554-560.	1.3	5
94	Ophthalmic Application of Anti-VEGF Therapy. Asia-Pacific Journal of Ophthalmology, 2017, 6, 479-480.	1.3	6
95	Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age. Clinical Ophthalmology, 2017, Volume 11, 1197-1201.	0.9	7
96	Macular Bruch's membrane defect and dome-shaped macula in high myopia. PLoS ONE, 2017, 12, e0178998.	1.1	49
97	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization. Clinical Ophthalmology, 2017, Volume 11, 1741-1746.	0.9	10
98	Clobal prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. British Journal of Ophthalmology, 2018, 102, 855-862.	2.1	198
99	INTEROCULAR ASYMMETRY IN CHOROIDAL THICKNESS AND RETINAL SENSITIVITY IN HIGH MYOPIA. Retina, 2018, 38, 1620-1628.	1.0	11
100	Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Progress in Retinal and Eye Research, 2018, 63, 92-106.	7.3	125
101	LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY. Retina, 2018, 38, 2228-2238.	1.0	32
102	Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group. British Journal of Ophthalmology, 2018, 102, 455-459.	2.1	14
103	Multimodal imaging of linear lesions in the fundus of pathologic myopic eyes with macular lesions. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 71-81.	1.0	7
104	Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain. International Journal of Molecular Sciences, 2018, 19, 2993.	1.8	5
105	Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan. Eye, 2018, 32, 1871-1878.	1.1	10
106	Fundus Photography and Angiography. ESASO Course Series, 2018, , 1-18.	0.1	0
107	Computational Approach to Investigating Key GO Terms and KEGG Pathways Associated with CNV. BioMed Research International, 2018, 2018, 1-9.	0.9	3
108	Novel Predictors of Visual Outcome in Anti-VEGF Therapy for Myopic Choroidal Neovascularization Derived Using OCT Angiography. Ophthalmology Retina, 2018, 2, 1118-1124.	1.2	6
109	Possible connection of short posterior ciliary arteries toÂ <i>choroidalÂneovascularisations in eyes with pathologic myopia</i> . British Journal of Ophthalmology, 2019, 103, 457-462.	2.1	36
110	FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA. Retina, 2019, 39, 1289-1298.	1.0	24

	CITATION R	EPORT	
#	Article	IF	CITATIONS
111	Changes in Choroidal Thickness and Choroidal Blood Perfusion in Guinea Pig Myopia. , 2019, 60, 3074.		120
112	Real-time OCT guidance and multimodal imaging monitoring of subretinal injection induced choroidal neovascularization in rabbit eyes. Experimental Eye Research, 2019, 186, 107714.	1.2	20
113	Diagnostic accuracy of optical coherence tomography angiography for choroidal neovascularization: a systematic review and meta-analysis. BMC Ophthalmology, 2019, 19, 162.	0.6	14
114	OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 759-768.	1.0	1
115	Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the <scp>MYRROR</scp> study. Acta Ophthalmologica, 2019, 97, e729-e735.	0.6	6
116	RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2019, 39, 1985-1994.	1.0	26
117	Myopic traction maculopathy biomarkers on optical coherence tomography angiography—An overlooked mechanism of visual acuity correction in myopic eyes. Eye, 2019, 33, 1305-1313.	1.1	15
118	Myopic Choroidal Neovascularization: Diagnosis and Treatment Update. Current Ophthalmology Reports, 2019, 7, 59-65.	0.5	0
119	Long-term Outcomes of Macular Hole Retinal Detachment in Highly Myopic Eyes after Surgical Reattachment. Korean Journal of Ophthalmology: KJO, 2019, 33, 539.	0.5	6
120	Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology, 2019, 2019, 1-6.	0.6	4
121	Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmologica, 2019, 97, e813-e814.	0.6	13
122	Imaging in myopia: potential biomarkers, current challenges and future developments. British Journal of Ophthalmology, 2019, 103, 855-862.	2.1	57
123	Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12â€month results from a randomized controlled study. Clinical and Experimental Ophthalmology, 2019, 47, 250-258.	1.3	10
124	Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN). Progress in Retinal and Eye Research, 2019, 69, 80-115.	7.3	227
125	Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 485-493.	1.0	5
126	APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2019, 39, 712-718.	1.0	17
127	Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study. European Journal of Ophthalmology, 2020, 30, 1069-1075.	0.7	6
128	Neural (Sensory) Retina. , 2020, , 407-480.e12.		2

#	Article	IF	CITATIONS
129	Updates on Myopia. , 2020, , .		16
130	Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. Acta Ophthalmologica, 2020, 98, e309-e315.	0.6	20
131	ABRUPTLY EMERGING VESSELS IN EYES WITH MYOPIC PATCHY CHORIORETINAL ATROPHY. Retina, 2020, 40, 1215-1223.	1.0	5
132	ASSESSING THE ACTIVITY OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2020, 40, 1757-1764.	1.0	18
133	Natural course of the intraretinal hyperreflective sign after macular haemorrhage absorption in eyes with pathologic myopia. Acta Ophthalmologica, 2020, 98, e631.	0.6	0
134	Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia. International Ophthalmology, 2020, 40, 833-839.	0.6	1
135	Serum Metabolomics Reveals Personalized Metabolic Patterns for Macular Neovascular Disease Patient Stratification. Journal of Proteome Research, 2020, 19, 699-707.	1.8	15
136	Hyperreflective Material in Optical Coherence Tomography Images of Eyes with Myopic Choroidal Neovascularization May Affect the Visual Outcome. Journal of Clinical Medicine, 2020, 9, 2394.	1.0	1
137	Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. European Journal of Ophthalmology, 2021, 31, 2481-2487.	0.7	8
138	Prevalence and predictors of myopic macular degeneration among Asian adults: pooled analysis from the Asian Eye Epidemiology Consortium. British Journal of Ophthalmology, 2021, 105, 1140-1148.	2.1	19
139	Does the Cilioretinal Artery Preserve Vision in High Myopia?. Ophthalmology Retina, 2020, 4, 963-964.	1.2	1
140	Late-phase hypercyanescence during indocyanine green angiography for assessment of myopic choroidal neovascularization. European Journal of Ophthalmology, 2020, 31, 112067212095174.	0.7	2
141	Morphologic Features of Myopic Choroidal Neovascularization in Pathologic Myopia on Swept-Source Optical Coherence Tomography. Frontiers in Medicine, 2020, 7, 615902.	1.2	11
142	Pathologic myopia: an overview of the current understanding and interventions. Global Health & Medicine, 2020, 2, 151-155.	0.6	6
143	The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization. Current Eye Research, 2020, 45, 1415-1421.	0.7	10
144	Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. Journal of Clinical Medicine, 2020, 9, 1934.	1.0	8
145	Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept. Current Eye Research, 2020, 45, 1467-1476.	0.7	6
146	Usefulness of Denoising Process to Depict Myopic Choroidal Neovascularisation Using a Single Optical Coherence Tomography Angiography Image. Scientific Reports, 2020, 10, 6172.	1.6	12

#	Article	IF	Citations
147	<p>Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia</p> . Clinical Ophthalmology, 2020, Volume 14, 853-873.	0.9	20
148	Optic disc edema due to peripapillary choroidal neovascularization. Taiwan Journal of Ophthalmology, 2021, 11, 93.	0.3	2
149	Myopic Macular Retinoschisis. , 2021, , 295-315.		1
150	Choroidal Neovascularization. , 2021, , 271-293.		0
151	Update on the Pathology of Pathological Myopia. , 2021, , 107-119.		0
152	Flow pattern and perforating vessels in three different phases of myopic choroidal neovascularization seen by swept-source optical coherence tomography angiography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2615-2624.	1.0	3
153	Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a realâ€world setting in China. BMC Ophthalmology, 2021, 21, 116.	0.6	4
154	Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic choroidal neovascularisation. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318440.	2.1	4
156	Visual Performance of Center-distance Multifocal Contact Lenses Fit Using a Myopia Control Paradigm. Optometry and Vision Science, 2021, 98, 272-279.	0.6	19
157	Refractive correction regulated gradient AC/A ratio with low-to-moderate myopia in children and adolescents. International Ophthalmology, 2021, 41, 2705-2710.	0.6	0
158	Dilated choroidal veins and their role in recurrences of myopic macular neovascularisations. British Journal of Ophthalmology, 2022, 106, 1429-1435.	2.1	5
159	A Multimodal Imaging–Based Deep Learning Model for Detecting Treatment-Requiring Retinal Vascular Diseases: Model Development and Validation Study. JMIR Medical Informatics, 2021, 9, e28868.	1.3	17
160	IMI Pathologic Myopia. , 2021, 62, 5.		140
161	Retinal photograph-based deep learning algorithms for myopia and a blockchain platform to facilitate artificial intelligence medical research: a retrospective multicohort study. The Lancet Digital Health, 2021, 3, e317-e329.	5.9	78
162	ROLE OF DILATED SUBFOVEAL CHOROIDAL VEINS IN EYES WITH MYOPIC MACULAR NEOVASCULARIZATION. Retina, 2021, 41, 1063-1070.	1.0	11
163	Feasibility and tolerability of ophthalmic virtual reality as a medical communication tool in children and young people. Acta Ophthalmologica, 2021, , .	0.6	4
164	Multimodal Imaging Characteristics and Presumed Cause of Intrapapillary Hemorrhage with Adjacent Peripapillary Subretinal Hemorrhage. Clinical Ophthalmology, 2021, Volume 15, 2583-2590.	0.9	3
165	A Review of Aflibercept Treatment for Macular Disease. Ophthalmology and Therapy, 2021, 10, 413-428.	1.0	13

#	Article	IF	Citations
166	Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3295-3303.	1.0	2
167	Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children. Ophthalmology, 2021, 128, 816-826.	2.5	55
168	Anti-VEGF Therapy in Myopic CNV. Current Drug Targets, 2021, 22, 1054-1063.	1.0	7
169	Modern diagnostic and therapeutic approaches in familial maculopathy with reference to North Carolina macular dystrophy. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 418-427.	0.2	2
170	Eph Receptors and Ephrins in Retinal Diseases. International Journal of Molecular Sciences, 2021, 22, 6207.	1.8	6
171	Myopic foveal detachment associated with pachychoroid characteristics. BMC Ophthalmology, 2021, 21, 288.	0.6	1
172	Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opinion on Drug Safety, 2022, 21, 43-54.	1.0	9
173	RELATIONSHIP BETWEEN MYOPIC CHOROIDAL NEOVASCULARIZATION ACTIVITY AND PERFORATING SCLERAL VESSELS IN HIGH MYOPIA. Retina, 2022, 42, 204-209.	1.0	11
174	Beyond the Visual Acuity: Assessing the Visual Function in mCNV Patients After Anti-VEGF Treatment. Frontiers in Medicine, 2021, 8, 709584.	1.2	0
175	A Three-Dimensional-reconstruction-based study on the ocular volume of Chinese children with high myopia. BMC Ophthalmology, 2021, 21, 326.	0.6	0
176	Retinal applications of swept source optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). Progress in Retinal and Eye Research, 2021, 84, 100951.	7.3	134
177	CORRELATION BETWEEN ATROPHY-TRACTION-NEOVASCULARIZATION GRADE FOR MYOPIC MACULOPATHY AND CLINICAL SEVERITY. Retina, 2021, 41, 1867-1873.	1.0	9
178	Joint disease classification and lesion segmentation via one-stage attention-based convolutional neural network in OCT images. Biomedical Signal Processing and Control, 2022, 71, 103087.	3.5	11
179	Epidemiology of Myopia, High Myopia, and Pathological Myopia. , 2021, , 17-41.		0
180	Angiogenesis-Based Therapies for Eye Diseases. , 2017, , 259-297.		2
181	Introduction and Overview on Myopia: A Clinical Perspective. , 2020, , 1-26.		1
182	Imaging in Myopia. , 2020, , 219-239.		4
183	Analysis of Fundus Shape in Highly Myopic Eyes by Using Curvature Maps Constructed from Optical Coherence Tomography. PLoS ONE, 2014, 9, e107923.	1.1	30

#	Article	IF	CITATIONS
184	Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study. PLoS ONE, 2015, 10, e0128403.	1.1	14
185	Choroidal Thickness in Acute Non-arteritic Anterior Ischemic Optic Neuropathy. Journal of Ophthalmic and Vision Research, 2020, 15, 59-68.	0.7	7
186	Transpupillary Thermotherapy of Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 12-17.	0.4	1
187	Choriocapillary Blood Flow in Myopic Subjects Measured With OCT Angiography. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, e133-e139.	0.4	17
188	Insight into high myopia and the macula. Indian Journal of Ophthalmology, 2017, 65, 85.	0.5	28
189	Choroidal neovascularization secondary to pathological myopia. World Journal of Ophthalmology, 2014, 4, 35.	0.1	1
190	Corneal Haze, Refractive Surgery, and Implications for Choroidal Neovascularization. , 2018, , 439-477.		0
191	Indocyanine Green-Enhanced Dual Photoacoustic Microscopy and Fluorescence Imaging for Visualization of Choroidal Neovascularization in a Rabbit Model. , 2019, , .		0
192	Characteristics of Recurrence in Patients with Polypoidal Choroidal Vasculopathy and Myopic Choroidal Neovascularization. Journal of Retina, 2019, 4, 1-9.	0.1	0
193	Clinical Management of Myopia in Adults: Treatment of Myopic CNV. , 2020, , 271-288.		0
194	Myopic Maculopathy Due to Pathologic Myopia. Retina Atlas, 2020, , 49-54.	0.0	0
195	Clinical Trials Related to Myopic Choroidal Neovascularization. , 2020, , 283-295.		1
196	Comparison of Retinal Layer Thicknesses of Highly Myopic Eyes and Normal Eyes. Korean Journal of Ophthalmology: KJO, 2020, 34, 469-477.	0.5	9
197	Overview of Fundus Lesions Associated with Pathologic Myopia. , 2020, , 9-15.		0
198	Myopic Macular Neovascularization; Treatment Outcome (Including MP3). , 2020, , 69-75.		1
199	Peripapillary Choroidal Neovascularization. , 2020, , 187-201.		0
200	Deep learning models for screening of high myopia using optical coherence tomography. Scientific Reports, 2021, 11, 21663.	1.6	15
201	Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization. Scientific Reports, 2021, 11, 21947.	1.6	0

#	Article	IF	CITATIONS
202	Oculocardiac Reflex During Intravitreal Injection. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2020, 9, 111-117.	0.4	3
203	Mechanism of Hypoxia Inducible Factor-1α (HIF-1α) in Choroidal Neovascularization in Macular Lutea of High Myopia. Journal of Biomaterials and Tissue Engineering, 2022, 12, 105-111.	0.0	0
204	Automatic Segment and Quantify Choroid Layer in Myopic eyes: Deep Learning based Model. Seminars in Ophthalmology, 2022, , 1-8.	0.8	0
205	RESPONSE TO TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN HIGHLY MYOPIC EYES WITH DOME-SHAPED MACULA. Retina, 2022, 42, 1057-1064.	1.0	1
206	Discerning Between Macular Hemorrhages Due to Macular Neovascularization or Due to Spontaneous Bruch's Membrane Rupture in High Myopia: A Comparative Analysis Between OCTA and Fluorescein Angiography. Ophthalmology and Therapy, 2022, 11, 821-831.	1.0	8
207	A systematic review of clinical practice guidelines for myopic macular degeneration. Journal of Global Health, 2022, 12, 04026.	1.2	9
208	Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. British Journal of Ophthalmology, 2023, 107, 1043-1050.	2.1	8
209	Pathologic myopia: advances in imaging and the potential role of artificial intelligence. British Journal of Ophthalmology, 2023, 107, 600-606.	2.1	10
210	The Potential of Current Polygenic Risk Scores to Predict High Myopia and Myopic Macular Degeneration in Multiethnic Singapore Adults. Ophthalmology, 2022, 129, 890-902.	2.5	5
211	Progression of myopia in teenagers and adults: a nationwide longitudinal study of a prevalent cohort. British Journal of Ophthalmology, 2023, 107, 644-649.	2.1	5
212	Pathologic Myopia. , 2022, , 3705-3717.		0
213	Predictors of myopic macular degeneration in a 12-year longitudinal study of Singapore adults with myopia. British Journal of Ophthalmology, 2023, 107, 1363-1368.	2.1	10
214	Predicting lesion shrinkage in eyes with myopic choroidal neovascularization from features on optical coherence tomography angiography. Retina, 2022, Publish Ahead of Print, .	1.0	2
215	An Artificial-Intelligence–Based Automated Grading and Lesions Segmentation System for Myopic Maculopathy Based on Color Fundus Photographs. Translational Vision Science and Technology, 2022, 11, 16.	1.1	12
216	Advances in OCT Imaging in Myopia and Pathologic Myopia. Diagnostics, 2022, 12, 1418.	1.3	9
217	Detection of macular findings in highly myopic eyes with OCT and to correlate it to various visual parameters. Indian Journal of Clinical and Experimental Ophthalmology, 2022, 8, 233-238.	0.1	0
218	Characteristics of choroidal neovascularization in elderly eyes with high myopia not meeting the pathologic myopia definition. Scientific Reports, 2022, 12, .	1.6	2
219	Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits. Experimental Eye Research, 2022, 223, 109215.	1.2	6

#	Article	IF	CITATIONS
220	OCT Analysis of Retinal Pigment Epithelium in Myopic Choroidal Neovascularization: Correlation Analysis with Different Treatments. Journal of Clinical Medicine, 2022, 11, 5023.	1.0	1
221	Prognostic value of myopic disk deformation in myopic choroidal neovascularization: A 6-year follow-up study. Frontiers in Medicine, 0, 9, .	1.2	0
223	Factors associated with the recurrence of choroidal neovascularization in pathologic myopia. Frontiers in Medicine, 0, 9, .	1.2	1
224	Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. PLoS ONE, 2022, 17, e0273613.	1.1	3
225	Focal Choroidal Thickness hemodynamics as a sign of macular neovascularization (MNV) activity in pathologic myopia. Retina, 2022, Publish Ahead of Print, .	1.0	2
227	Diagnostic accuracy of OCTA and OCT for myopic choroidal neovascularisation: a systematic review and meta-analysis. Eye, 2023, 37, 21-29.	1.1	5
228	Long-term clinical effects of intravitreal injections of conbercept for the treatment of choroidal neovascularization in patients with pathological myopia. International Journal of Ophthalmology, 2022, 15, 1971-1977.	0.5	2
229	Higher Circulating Levels of Neutrophils and Basophils Are Linked to Myopic Retinopathy. International Journal of Molecular Sciences, 2023, 24, 80.	1.8	5
230	Global trends and frontiers of research on pathologic myopia since the millennium: A bibliometric analysis. Frontiers in Public Health, 0, 10, .	1.3	3
231	Assessment of mouse VEGF neutralization by ranibizumab and aflibercept. PLoS ONE, 2022, 17, e0278951.	1.1	1
232	Intravitreal Bevacizumab for the Treatment of Myopic Choroidal Neovascularisation in an Asian Population. Annals of the Academy of Medicine, Singapore, 2010, 39, 493-494.	0.2	2
233	Myopic macular diseases: A review. Clinical and Experimental Ophthalmology, 2023, 51, 229-242.	1.3	4
234	Myopia: Histology, clinical features, and potential implications for the etiology of axial elongation. Progress in Retinal and Eye Research, 2023, 96, 101156.	7.3	22
236	Characteristics and response of subretinal hyperreflective material to anti-vascular endothelial growth factor in myopic choroidal neovascularization. Scientific Reports, 2023, 13, .	1.6	0
237	Extreme myopia is more susceptible to SOX2 gene than high myopia. Experimental Eye Research, 2023, 230, 109435.	1.2	0
238	From mouse to human: Accessing the biochemistry of vision in vivo by two-photon excitation. Progress in Retinal and Eye Research, 2023, 93, 101170.	7.3	6
250	Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials. BioDrugs, 2023, 37, 843-854.	2.2	0
256	A Super Token Vision Transformer and CNN Parallel Branch Network for mCNV Lesion Segmentation in OCT Images. Lecture Notes in Computer Science, 2024, , 267-276.	1.0	0

ARTICLE

IF CITATIONS